Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Reconstitute at 0.5 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for NKG2C/CD159c/KLRC2 Antibody (134591) [Unconjugated]
CD159 antigen-like family member C
killer cell lectin-like receptor subfamily C, member 2
NK cell receptor C
NKG2-C type II integral membrane protein
NKG2CNKG2-C-activating NK receptor
Human NKG2C (NK cell Group 2 isoform C; Killer
cell lectin-like receptor subfamily C, member 2) is a member of the C-type
lectin-like superfamily of proteins. Natural
killer (NK) receptors are expressed in both NK cells and cytotoxic CD8+
T cells and have both activating and inhibitory members (1-3). Regulation of the balance between the
activating and inhibitory receptors is important and lack of such regulation
has been implicated in autoimmunity (4).
The NKG2 family includes seven receptors:
NKG2A, -B, -C, -D, -E, -F, and -H, which is the longer isoform of NKG2E. Except for NKG2D and NKG2F, the NKG2 family
members form heterodimers with CD94 (5, 6).
NKG2C interacts with the adapter molecule DAP12 and acts as activating
receptor when heterodimerized with CD94 (7).
Human NKG2C is synthesized as a 231 amino acid (aa) protein that includes a 70 aa
cytoplasmic domain, a 23 aa transmembrane segment, and a 138 aa extracellular
domain (ECD). Within the ECD, human NKG2C
shares 40% sequence identity with mouse NKG2C. NKG2C-CD94
heterodimers bind to the widely expressed nonclassical MHC-I molecule, HLA-E
(Qa-1b in mouse), which presents a peptide derived from the signal peptide of
classical MHC-I molecules (8, 9). Triggering the NKG2C-CD94 complex may
activate the cytolytic activity and cytokine production of NK and CD8+ T cells
(8, 10). Human cytomegalovirus (HCMV) infection promotes the differentiation
and expansion of NKG2C+ NK cell subsets, possibly involving a cognate interaction
of CD94/NKG2C with ligand(s) displayed by HCMV‑infected cells (11, 12).
Orbelyan, G.A. et al. (2014) J. Immunol. 193:610.
Tassi I. et al. (2006) Immnunol Rev. 214:92.
Lanier, L.L. (2008) Nat. Immunol. 9:495.
Schleinitz, N. et al. (2010) Immunology. 174:2878.
Lopez-Botet, M. et al. (2000) Hum. Immunol. 61:7.
Braud, V.M. et al. (1998) Nature. 391:795.
Lanier, L.L. (1998) Immunity 8:693.
Vance, R.E. et al. (1999) J Exp Med 190:1801.
Kaiser B.K. et al. (2005) J Immunol 174:2878.
Bellón T. et al. (1999) J Immunol 162:3996.
Pupuleku A. et al. (2017) Front Immunol. 8:1317.
Hammer Q. et al. (2018) Nat Immunol. 19:453.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our NKG2C/CD159c/KLRC2 Antibody (134591) [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.